Search - tctmd.com

Displaying 1 - 20 of 62

Sort: Relevancy | Date

Presentation TCT 2024

Patient-Reported Outcomes are a True Measure of TTVI Value

Presenter: John Spertus

October 30, 2024

Presentation TCT 2024

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Presenter: Ori Ben-Yehuda

October 30, 2024

Presentation TCT 2024

Transcatheter VIV (With Appropriate Leaflet Modification) Will Dominate!

Presenter: Adam Greenbaum

October 30, 2024

Presentation TCT 2024

Re-Do Surgery has Clear Long-Term Advantages and is Preferred!

Presenter: Michael Bowdish

October 30, 2024

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

Presentation TCT 2023

Can We Do Better? Next Generation LAAO Devices

Presenter: Saibal Kar

October 26, 2023

Presentation TCT 2023

Ultimate Stroke Prevention: LAAO in Association With Medical Therapy/Other Procedures

Presenter: Amar Krishnaswamy

October 26, 2023

Presentation TCT 2023

LAAO as First Line Stroke Prevention Therapy: Are CHAMPION-AF and CATALYST Trials Likely to Succeed?

Presenter: Vivek Reddy

October 26, 2023

Presentation TCT 2023

No: The Transcatheter Devices Have Much Better Results

Presenter: Torsten Vahl

October 26, 2023

Presentation TCT 2023

Yes: Based on LAAOS III, All LAA Should Be Ligated at the Time of Concurrent Heart Surgery

Presenter: Isaac George

October 26, 2023

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

L.A. McKeown

September 18, 2022

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Shelley Wood

October 09, 2020

Presentation TCT 2019

Flash Debate: TAVR in the Moderate-Risk Bleeding Patient With AF ⁠— Medical Therapy Is Best!

Presenter: Freek Verheugt

September 28, 2019

Presentation TCT 2019

Flash Debate: TAVR in the Moderate-Risk Bleeding Patient With AF ⁠— Close the LAA!

Presenter: Kishore Harjai

September 28, 2019

Presentation TCT 2018

COUNTERPOINT: Focus on the Severity of TR

Presenter: Steven F. Bolling

September 23, 2018

Presentation TCT 2018

POINT: The Case for Aggressive TR Repair During Mitral Valve Surgery

Presenter: Paolo Denti

September 23, 2018

Presentation TCT 2018

Opinion Patient Preferences and Shared Decision-Making Requires Open Access to Both TAVR and SAVR

Presenter: Megan Coylewright

September 22, 2018

Presentation TCT 2018

Counterpoint SAVR Is the Gold Standard and Deserves Priority Treatment!

Presenter: Alfredo Trento

September 22, 2018

Presentation TCT 2018

Point Parity Should Include Valve Assessments, Regulatory Standards, and Equal Patient Access

Presenter: Michael J. Mack

September 22, 2018

Presentation TCT 2018

Opinion Tiered Systems of Care Are Preferred to Optimize Patient Care In Valvular Heart Disease

Presenter: Patrick T. O'Gara

September 22, 2018

Advertisement

Patient-Reported Outcomes are a True Measure of TTVI Value

CV Event Reduction is the Essential Criterion for Implementing New Device Therapies

Transcatheter VIV (With Appropriate Leaflet Modification) Will Dominate!

Re-Do Surgery has Clear Long-Term Advantages and is Preferred!

What’s Going to Be Big at TCT 2024?

Can We Do Better? Next Generation LAAO Devices

Ultimate Stroke Prevention: LAAO in Association With Medical Therapy/Other Procedures

LAAO as First Line Stroke Prevention Therapy: Are CHAMPION-AF and CATALYST Trials Likely to Succeed?

No: The Transcatheter Devices Have Much Better Results

Yes: Based on LAAOS III, All LAA Should Be Ligated at the Time of Concurrent Heart Surgery

FLASH: More Data to Support Mechanical Thrombectomy in PE

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Flash Debate: TAVR in the Moderate-Risk Bleeding Patient With AF ⁠— Medical Therapy Is Best!

Flash Debate: TAVR in the Moderate-Risk Bleeding Patient With AF ⁠— Close the LAA!

COUNTERPOINT: Focus on the Severity of TR

POINT: The Case for Aggressive TR Repair During Mitral Valve Surgery

Opinion Patient Preferences and Shared Decision-Making Requires Open Access to Both TAVR and SAVR

Counterpoint SAVR Is the Gold Standard and Deserves Priority Treatment!

Point Parity Should Include Valve Assessments, Regulatory Standards, and Equal Patient Access

Opinion Tiered Systems of Care Are Preferred to Optimize Patient Care In Valvular Heart Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content